CARMUSTINE

N/A

Manufactured by Azurity Pharmaceuticals, Inc.

8,401 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CARMUSTINE

CARMUSTINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Azurity Pharmaceuticals, Inc.. The most commonly reported adverse reactions for CARMUSTINE include OFF LABEL USE, FEBRILE NEUTROPENIA, MYELODYSPLASTIC SYNDROME, DISEASE PROGRESSION, THROMBOCYTOPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARMUSTINE.

Top Adverse Reactions

OFF LABEL USE494 reports
FEBRILE NEUTROPENIA358 reports
MYELODYSPLASTIC SYNDROME290 reports
DISEASE PROGRESSION278 reports
THROMBOCYTOPENIA242 reports
PYREXIA236 reports
NEUTROPENIA204 reports
MUCOSAL INFLAMMATION200 reports
PNEUMONIA194 reports
DRUG INEFFECTIVE183 reports
ACUTE MYELOID LEUKAEMIA171 reports
INFECTION171 reports
SEPSIS156 reports
DIARRHOEA155 reports
PRODUCT USE IN UNAPPROVED INDICATION152 reports
BRAIN OEDEMA137 reports
MALIGNANT NEOPLASM PROGRESSION121 reports
ANAEMIA116 reports
DEATH112 reports
SECOND PRIMARY MALIGNANCY110 reports
PANCYTOPENIA103 reports
SEPTIC SHOCK97 reports
NAUSEA89 reports
MALIGNANT TRANSFORMATION88 reports
RESPIRATORY FAILURE82 reports
PULMONARY EMBOLISM81 reports
VOMITING81 reports
ACUTE KIDNEY INJURY78 reports
LEUKOPENIA77 reports
CYTOMEGALOVIRUS INFECTION75 reports
DIFFUSE LARGE B CELL LYMPHOMA RECURRENT72 reports
STOMATITIS71 reports
HEADACHE69 reports
NEUROPATHY PERIPHERAL69 reports
THERAPY PARTIAL RESPONDER69 reports
DYSPNOEA68 reports
NON HODGKIN^S LYMPHOMA RECURRENT68 reports
VENOOCCLUSIVE LIVER DISEASE67 reports
INTENTIONAL PRODUCT USE ISSUE66 reports
STAPHYLOCOCCAL INFECTION65 reports
ACUTE RESPIRATORY DISTRESS SYNDROME64 reports
COLITIS64 reports
HAEMATOTOXICITY64 reports
PLATELET COUNT DECREASED64 reports
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY64 reports
CONVULSION63 reports
DISEASE RECURRENCE63 reports
TOXICITY TO VARIOUS AGENTS63 reports
LYMPHADENOPATHY58 reports
ASPERGILLUS INFECTION57 reports
FATIGUE57 reports
ATRIAL FIBRILLATION56 reports
ASTHENIA55 reports
DIFFUSE LARGE B CELL LYMPHOMA55 reports
HYPOTENSION54 reports
RASH54 reports
STEM CELL TRANSPLANT54 reports
ALANINE AMINOTRANSFERASE INCREASED52 reports
MYELOSUPPRESSION52 reports
DEEP VEIN THROMBOSIS51 reports
NEUTROPENIC SEPSIS51 reports
RENAL FAILURE51 reports
MYOSITIS50 reports
PNEUMOCYSTIS JIROVECII PNEUMONIA50 reports
BASAL CELL CARCINOMA49 reports
CONDITION AGGRAVATED49 reports
CYTOPENIA49 reports
PNEUMONITIS48 reports
DRUG INTERACTION46 reports
LYMPHOMA45 reports
BRONCHOPULMONARY ASPERGILLOSIS44 reports
CYTOMEGALOVIRUS INFECTION REACTIVATION44 reports
NEOPLASM PROGRESSION44 reports
RENAL IMPAIRMENT42 reports
FEBRILE BONE MARROW APLASIA41 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME41 reports
BONE MARROW FAILURE40 reports
BACTERAEMIA39 reports
POST PROCEDURAL COMPLICATION39 reports
ABDOMINAL PAIN38 reports
CARDIAC FAILURE38 reports
PNEUMOCEPHALUS38 reports
CARDIOTOXICITY37 reports
COUGH37 reports
CYTOKINE RELEASE SYNDROME37 reports
HEMIPLEGIA37 reports
PULMONARY TOXICITY37 reports
BLOOD STEM CELL TRANSPLANT FAILURE36 reports
GRAFT VERSUS HOST DISEASE36 reports
HYPOGAMMAGLOBULINAEMIA36 reports
LYMPHOPENIA36 reports
NEUTROPHIL COUNT DECREASED36 reports
VENOOCCLUSIVE DISEASE36 reports
WHITE BLOOD CELL COUNT DECREASED36 reports
ACUTE GRAFT VERSUS HOST DISEASE35 reports
CONFUSIONAL STATE35 reports
HEPATOTOXICITY35 reports
MUSCULAR WEAKNESS35 reports
PLEURAL EFFUSION35 reports
CEREBRAL INFARCTION34 reports

Report Outcomes

Out of 4,480 classified reports for CARMUSTINE:

Serious 97.9%Non-Serious 2.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male2,172 (62.0%)
Female1,254 (35.8%)
Unknown76 (2.2%)

Reports by Age

Age 64111 reports
Age 61104 reports
Age 6296 reports
Age 6895 reports
Age 5992 reports
Age 5791 reports
Age 5488 reports
Age 6084 reports
Age 5680 reports
Age 5578 reports
Age 4776 reports
Age 6775 reports
Age 6966 reports
Age 6363 reports
Age 4162 reports
Age 4061 reports
Age 5161 reports
Age 5861 reports
Age 3560 reports
Age 7060 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CARMUSTINE?

This profile reflects 8,401 FDA FAERS reports that mention CARMUSTINE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CARMUSTINE?

Frequently reported terms in FAERS include OFF LABEL USE, FEBRILE NEUTROPENIA, MYELODYSPLASTIC SYNDROME, DISEASE PROGRESSION, THROMBOCYTOPENIA, PYREXIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CARMUSTINE?

Labeling and FAERS entries often list Azurity Pharmaceuticals, Inc. in connection with CARMUSTINE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.